The estimated Net Worth of Charles A. Iii Reinhart is at least $2.38 Million dollars as of 6 June 2023. Mr. Reinhart owns over 2,607 units of Pacira BioSciences Inc stock worth over $437,138 and over the last 9 years he sold PCRX stock worth over $555,972. In addition, he makes $1,389,740 as Chief Financial Officer at Pacira BioSciences Inc.
Sign up
Mr. Reinhart PCRX stock SEC Form 4 insiders trading
Charles has made over 6 trades of the Pacira BioSciences Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 2,607 units of PCRX stock worth $100,109 on 6 June 2023.
The largest trade he's ever made was selling 2,648 units of Pacira BioSciences Inc stock on 4 June 2021 worth over $161,634. On average, Charles trades about 692 units every 114 days since 2016. As of 6 June 2023 he still owns at least 33,626 units of Pacira BioSciences Inc stock.
You can see the complete history of Mr. Reinhart stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Charles Reinhart biography
Charles A. Reinhart III serves as Chief Financial Officer of the Company., is Chief Financial Officer of the Company. Prior to joining Pacira, he was the Chief Financial Officer at Covis Pharmaceuticals, Inc., a specialty pharmaceutical company, from September 2014 to October 2015. From September 2011 to August 2014, he served as Executive Vice President and Chief Financial Officer of Archimedes Pharma Ltd., a specialty pharmaceutical company. Mr. Reinhart also served as Senior Vice President and Chief Financial Officer of PharmAthene, Inc., a biodefense company engaged in the development of next generation medical countermeasures against biological and chemical threats, from 2009 to 2011. In addition, Mr. Reinhart has previously held senior financial roles at Millennium Pharmaceuticals, Inc., Cephalon, Inc. and several early-stage life sciences companies. Mr. Reinhart earned his Bachelor of Science degree from Lehigh University and his MBA from the Wharton School of the University of Pennsylvania. He is also a CPA.
What is the salary of Charles Reinhart?
As the Chief Financial Officer of Pacira BioSciences Inc, the total compensation of Charles Reinhart at Pacira BioSciences Inc is $1,389,740. There are 6 executives at Pacira BioSciences Inc getting paid more, with David Stack having the highest compensation of $5,806,430.
How old is Charles Reinhart?
Charles Reinhart is 59, he's been the Chief Financial Officer of Pacira BioSciences Inc since 2016. There are 9 older and 12 younger executives at Pacira BioSciences Inc. The oldest executive at Pacira BioSciences Inc is Gary Pace, 72, who is the Independent Director.
What's Charles Reinhart's mailing address?
Charles's mailing address filed with the SEC is C/O PACIRA BIOSCIENCES, INC., 5401 WEST KENNEDY BOULEVARD, SUITE 890, TAMPA, FL, 33609.
Insiders trading at Pacira BioSciences Inc
Over the last 14 years, insiders at Pacira BioSciences Inc have traded over $321,391,130 worth of Pacira BioSciences Inc stock and bought 2,075,444 units worth $15,133,188 . The most active insiders traders include Advisors Llc Orbi Med Capit..., Carl L Gordon, and Andreas Wicki. On average, Pacira BioSciences Inc executives and independent directors trade stock every 13 days with the average trade being worth of $491,036. The most recent stock trade was executed by Marcelo Bigal on 16 August 2024, trading 1,512 units of PCRX stock currently worth $20,034.
What does Pacira BioSciences Inc do?
pacira pharmaceuticals, inc. (nasdaq: pcrx) is an emerging specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. the company's current emphasis is the development of non-opioid products for postsurgical pain control, and its lead product, exparel® (bupivacaine liposome injectable suspension), was commercially launched in the united states in april 2012. exparel and two other products have utilized the pacira proprietary product delivery technology depofoam®, a unique platform that encapsulates drugs without altering their molecular structure and then releases them over a desired period of time.
What does Pacira BioSciences Inc's logo look like?
Complete history of Mr. Reinhart stock trades at Pacira BioSciences Inc
Pacira BioSciences Inc executives and stock owners
Pacira BioSciences Inc executives and other stock owners filed with the SEC include:
-
David Stack,
Chairman of the Board, Chief Executive Officer -
Max Reinhardt,
President -
Dennis McLoughlin,
Chief Commercial Officer -
Kristen Williams,
Chief Administrative Officer, Secretary -
Roy Winston,
Chief Clinical Officer -
David M. Stack,
Chairman & CEO -
Charles Reinhart,
Chief Financial Officer -
Dr. Roy Winston M.D.,
Chief Medical Officer -
Christopher Christie,
Director -
Max Reinhardt,
Pres of Rest of World -
Dr. Jonathan Slonin M.D.,
Chief Clinical Officer -
Kristen Williams,
Chief Admin. Officer & Sec. -
Charles A. Reinhart III, CPA, M.B.A.,
Chief Financial Officer -
Paul Hastings,
Lead Independent Director -
Laura Brege,
Independent Director -
John Longenecker,
Independent Director -
Mark Kronenfeld,
Independent Director -
Yvonne Greenstreet,
Independent Director -
Mark Froimson,
Independent Director -
Gary Pace,
Independent Director -
Susan Mesco,
IR Contact Officer -
Andreas Wicki,
Independent Director -
Charles Laranjeira,
Chief Technical Officer -
Kristen Williams J.D.,
Chief Admin. Officer & Sec. -
Daryl Gaugler,
Chief Operating Officer -
Robert J. Weiland,
Sr. VP of Alliance Management -
Richard Kahr,
VP of HR -
Charles Laranjeira,
Chief Technical Officer -
Lauren Bullaro Riker,
Principal Accounting Officer & VP of Fin. -
Dennis L Winger,
Director -
Scott Braunstein,
SVP, Strategy & Corp. Dev. -
Robert J. Weiland,
Chief Commercial Officer -
Richard Scranton,
Chief Scientific Officer -
James B Jones,
SVP & Chief Medical Officer -
James S Scibetta,
Chief Financial Officer -
Gary Patou,
Director -
Taunia Markvicka,
Vice President, Commercial -
Advisors Llc Orbi Med Capit...,
-
Venture Partners Vi Lp Sand...,
-
Bio Ventures Iv Qp Lpmpm Bi...,
-
Bio Ventures Iv Qp Lp Scopa...,
-
Carl L Gordon,
Director -
Bio Ventures Iv Qp Lpmpm Bi...,
-
Venture Partners Vi Lp Sand...,
-
Luke Evnin,
Director -
John Pratt,
General Manager, San Diego -
Vaughn Mgadicke Ansbert Kai...,
-
Bioventures Cayman Ltd Hbm,
10% owner -
Fred A Middleton,
Director -
Venture Partners Vi Lp Sand...,
-
Venture Partners Vi Lp Sand...,
-
Abraham Ceesay,
Director -
Alethia Young,
Director -
Marcelo Bigal,
Director -
Michael J. Yang,
Director -
Donald C. Manning,
Chief Medical Officer -
Lauren Riker,
Senior Vice President, Finance -
Anthony Molloy,
Chief Lgl & Compliance Officer -
Daryl Gaugler,
Chief Operating Officer -
Ronald J. Jr. Ellis,
Chief Strategy Officer -
Jonathan Slonin,
Chief Medical Officer -
Frank D. Lee,
Chief Executive Officer